Market Cap : 229.24 M | Enterprise Value : 154.88 M | PE Ratio : At Loss | PB Ratio : 2.89 |
---|
NAS:VTGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:VTGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2022-05-19), the stock price of VistaGen Therapeutics is $1.11. VistaGen Therapeutics's graham number for the quarter that ended in Dec. 2021 was $N/A. Therefore, VistaGen Therapeutics's Price to Graham Number ratio for today is N/A.
The historical rank and industry rank for VistaGen Therapeutics's Graham Number or its related term are showing as below:
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
The historical data trend for VistaGen Therapeutics's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VistaGen Therapeutics's Graham Number, along with its competitors' market caps and Graham Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Graham Number distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Graham Number falls into.
Graham Number is a concept based on Ben Graham's conservative valuation of companies.
VistaGen Therapeutics's Graham Number for the fiscal year that ended in Mar. 2021 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI) |
= | sqrt of (22.5 | * | 0.509 | * | -0.49) |
= | N/A |
VistaGen Therapeutics's Graham Number for the quarter that ended in Dec. 2021 is calculated as
Graham Number | |||||
= | sqrt of (22.5 | * | Tangible Book per Share | * | EPS without NRI (TTM)) |
= | sqrt of (22.5 | * | 0.387 | * | -0.324) |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
VistaGen Therapeutics's Price to Graham number Ratio for today is calculated as
Price to Graham number | = | Share Price (Today) | / | Graham number (Q: Dec. 2021 ) |
= | 1.11 | / | N/A | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Thank you for viewing the detailed overview of VistaGen Therapeutics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.
Saxe Jon S | director | FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076 |
Dotson Jerrold Duane | officer: VP, CFO AND SECRETARY | 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035 |
Singh Shawn | director, officer: CHIEF EXECUTIVE OFFICER | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Snodgrass H. Ralph | director, officer: PRES./CHIEF SCIENTIFIC OFFICER | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Smith Mark Alan | officer: CHIEF MEDICAL OFFICER | 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Mcpartland Mark A. | officer: VP CORPORATE DEVELOPMENT | C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 |
Gin Jerry B | director | 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080 |
Underdown Brian J. | director | C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000 |
Cunningham Ann Michelle | director | 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335 |
Rice A. Franklin | officer: VP CORPORATE DEVELOPMENT | 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080 |
Bonfiglio Gregory A. | director | 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 |
Cato Holding Co | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Cato Allen Easley | 10 percent owner | 4364 SOUTH ALSTON AVENUE DURHAM NC 27713 |
Jones Stephanie | director, 10 percent owner, officer: PRESIDENT | 13834 W. HOYT ROAD RATHDRUM ID 83858 |
From GuruFocus
Other Sources
By Seekingalpha 2021-11-10
By tipranks.com 2022-02-13
By Seekingalpha 2021-01-24
By Zacks 2021-11-10
By Fool 2021-06-30
By Zacks 2021-06-16
By Zacks 2021-10-20
By Zacks 2021-08-12
By tipranks.com 2022-03-03
By Zacks 2022-04-05
By Seekingalpha 2022-02-10
By Zacks 2021-02-11
By Zacks 2022-02-10